A study looks at who is being tested for BRCA mutations as testing becomes more common. Also, a look at the impact of Zika virus on birth defects using benchmark data. Plus: How is the United States doing with infant mortality?
FDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies.
A 34-year-old Ohio woman was under the care of her longtime family physician, who had minor privileges to deliver uncomplicated pregnancies at a specific hospital, for her pregnancy. The woman is diagnosed with eclampsia in her third trimester and is immediately given a cesarean. After delivery, she is unresponsive having died from a massive intracranial hemorrhage. The physician is sued for fraudulently representing her abilities in obstetric care. What's the verdict?
Diagnosing ovarian cancer has been particularly difficult because physicians haven’t had access to accurate tools. As a result, they had to rely on identifying known symptoms, performing transvaginal ultrasounds, and testing for elevated CA-125 levels to catch the disease. But these methods aren’t foolproof, and ordering the wrong pelvic mass assessment test could endanger your patient and make you the target of a medical malpractice lawsuit.
A new study looks at whether breast density letters are too difficult for the typical woman to understand. Plus: The FDA issues a warning on fluconazole and miscarriage. Also, do irregular menses provide protection against ovarian cancer or increase risk?
Results of a multi center observational study suggest that testing for a panel of genes may be the wave of the future for hereditary breast and ovarian cancer and alter the course of clinical management.